Literature DB >> 22504872

Clinical features and prognostic factors for patients with bone metastases from prostate cancer.

Jian He1, Zhao-Chong Zeng, Ping Yang, Bing Chen, We Jiang, Shi-Suo Du.   

Abstract

To identify the clinical features and independent predictors of survival in patients with bone metastases from prostate cancer (PCa). We retrospectively analysed 115 PCa patients with bone metastases between 1997 and 2009. The overall survival rate after bone metastases was calculated using the Kaplan-Meier method. The prognostic factors were identified by univariate analysis using a log-rank test and by multivariate analysis using Cox proportional hazards regression models. The follow-up rate was 100%, the follow-up cases during 1, 3 and 5 years were 103, 79 and 55, respectively. The 1-, 3- and 5-year survival rates were 89.1%, 60.9% and 49.8%, respectively, with a median survival time of 48.5 months for patients with bone metastases from PCa. In univariate analysis, age, Gleason score, clinical stage, the number of bone lesions, alkaline phosphatase (ALP) level, invasion of neighbouring organs and non-regional lymph node metastases were correlated with prognosis. By multivariate analysis using Cox regression, ALP level, Gleason score and non-regional lymph node metastases were independent prognostic factors. These prognostic factors will help us to determine the appropriate dose and fraction of radiotherapy for these patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22504872      PMCID: PMC3720166          DOI: 10.1038/aja.2012.24

Source DB:  PubMed          Journal:  Asian J Androl        ISSN: 1008-682X            Impact factor:   3.285


  25 in total

1.  Nadir PSA level and time to PSA nadir following primary androgen deprivation therapy are the early survival predictors for prostate cancer patients with bone metastasis.

Authors:  T Sasaki; T Onishi; A Hoshina
Journal:  Prostate Cancer Prostatic Dis       Date:  2011-04-19       Impact factor: 5.554

2.  Prognostic factors in patients with metastatic (stage D2) prostate cancer: experience from the Scandinavian Prostatic Cancer Group Study-2.

Authors:  T Jørgensen; Y Kanagasingam; O Kaalhus; K J Tveter; M Bryne; F Skjørten; A Berner; H E Danielsen
Journal:  J Urol       Date:  1997-07       Impact factor: 7.450

3.  Metastatic carcinoma of the prostate: identifying prognostic groups using recursive partitioning.

Authors:  Tracy R Glass; Catherine M Tangen; E David Crawford; Ian Thompson
Journal:  J Urol       Date:  2003-01       Impact factor: 7.450

Review 4.  Tumor markers in prostate cancer I: blood-based markers.

Authors:  Shahrokh F Shariat; Axel Semjonow; Hans Lilja; Caroline Savage; Andrew J Vickers; Anders Bjartell
Journal:  Acta Oncol       Date:  2011-06       Impact factor: 4.089

5.  The significance of serum alkaline phosphatase bone isoenzyme in prostatic carcinoma with bony metastasis.

Authors:  S S Chen; K K Chen; A T Lin; Y H Chang; H H Wu; T H Hsu; L S Chang
Journal:  Br J Urol       Date:  1997-02

6.  [Bone metastasis as a sign of the existence of latent neoplasia].

Authors:  R Dallari; G L Gazzotti; P Barozzini; F Cervi; R Cavani
Journal:  Minerva Med       Date:  1986-05-31       Impact factor: 4.806

7.  Diagnostic techniques in prostatic cancer.

Authors:  J R Drago
Journal:  Postgrad Med       Date:  1986-07       Impact factor: 3.840

8.  Predictors of clinical metastasis in prostate cancer patients receiving androgen deprivation therapy: results from CaPSURE.

Authors:  Robert Abouassaly; Alan Paciorek; Charles J Ryan; Peter R Carroll; Eric A Klein
Journal:  Cancer       Date:  2009-10-01       Impact factor: 6.860

9.  Bone metastasis: Osteoblasts affect growth and adhesion regulons in prostate tumor cells and provoke osteomimicry.

Authors:  Kerstin Knerr; Karin Ackermann; Tanja Neidhart; Walter Pyerin
Journal:  Int J Cancer       Date:  2004-08-10       Impact factor: 7.396

10.  Clinical outcome of Taiwanese men with metastatic prostate cancer compared with other ethnic groups.

Authors:  Chung-Hsin Chen; Tzong-Shin Tzai; Shu-Pin Huang; Hsi-Chin Wu; Huai-Ching Tai; Yen-Hwa Chang; Yeong-Shiau Pu
Journal:  Urology       Date:  2008-04-18       Impact factor: 2.649

View more
  7 in total

1.  Prognostic factors in Chinese patients with metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy.

Authors:  Yuan-Yuan Qu; Bo Dai; Yun-Yi Kong; Ding-Wei Ye; Xu-Dong Yao; Shi-Lin Zhang; Hai-Liang Zhang; Chun-Guang Ma; Wei-Yi Yang
Journal:  Asian J Androl       Date:  2012-11-12       Impact factor: 3.285

2.  Overexpression of ETS-1 is associated with malignant biological features of prostate cancer.

Authors:  Bo Li; Yosuke Shimizu; Takashi Kobayashi; Naoki Terada; Koji Yoshimura; Tomomi Kamba; Yoshiki Mikami; Takahiro Inoue; Hiroyuki Nishiyama; Osamu Ogawa
Journal:  Asian J Androl       Date:  2012-10-15       Impact factor: 3.285

3.  Clinical features and treatment strategies for older prostate cancer patients with bone metastasis.

Authors:  Cheng Yang; Gui-Sheng Qi; Rui-Ming Rong; Jian He
Journal:  Asian J Androl       Date:  2013-09-16       Impact factor: 3.285

4.  Docetaxel with or without zoledronic acid for castration-resistant prostate cancer.

Authors:  Yue Pan; Haiyong Jin; Wei Chen; Zhixian Yu; Tingyu Ye; Yuancai Zheng; Zhiliang Weng; Feng Wang
Journal:  Int Urol Nephrol       Date:  2014-09-16       Impact factor: 2.370

5.  Elevated Serum Sialic Acid Levels Predict Prostate Cancer As Well As Bone Metastases.

Authors:  Cong Zhang; Lei Yan; Hongkai Song; Zheng Ma; Dongshan Chen; Feilong Yang; Liang Fang; Zeyan Li; Kui Li; Dawei Li; Nengwang Yu; Hainan Liu; Zhonghua Xu
Journal:  J Cancer       Date:  2019-01-01       Impact factor: 4.207

6.  Prognostic value of alkaline phosphatase in hormone-sensitive prostate cancer: a systematic review and meta-analysis.

Authors:  Keiichiro Mori; Florian Janisch; Mehdi Kardoust Parizi; Hadi Mostafaei; Ivan Lysenko; Dmitry V Enikeev; Shoji Kimura; Shin Egawa; Shahrokh F Shariat
Journal:  Int J Clin Oncol       Date:  2019-11-25       Impact factor: 3.402

Review 7.  Bone Health Management in the Continuum of Prostate Cancer Disease.

Authors:  Ettickan Boopathi; Ruth Birbe; Sunday A Shoyele; Robert B Den; Chellappagounder Thangavel
Journal:  Cancers (Basel)       Date:  2022-09-02       Impact factor: 6.575

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.